Key result
Novel KCNH2 and SLC4A3 variants alter repolarization in short QT syndrome, responsive to potassium channel blockers.
Why the study?
The clinical phenotypes and antiarrhythmic drug responses of novel KCNH2 and SLC4A3 variants in short QT syndrome remain incompletely characterized.
Observational
No
Answers are grounded in this paper and cite their sources.
May inform antiarrhythmic selection in short QT syndrome; hypothesis-generating and requires validation in larger cohorts.
VFventricular fibrillation SCD sudden cardiac death PQD PQ segment depression
No takes yet. Share an insight, caveat, or question.
Fukue et al. (2026) conducted an observational in Short QT syndrome (SQTS). Novel KCNH2 and SLC4A3 variants and potassium channel-blocking drugs vs. Between-family genotype comparison was evaluated on TpTec interval (Family 1 vs Family 2) (p=0.005). Novel KCNH2 and SLC4A3 variants in short QT syndrome were associated with distinct repolarization abnormalities, and potassium channel-blocking antiarrhythmic drugs successfully prolonged the QT interval.
Synapse has enriched 10 related papers. Consider them for comparative context: